knowledge -WSS

knowledge

author：focus 2025-09-06 06:00:09 - browse：19

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： New menopause drug shows promise in relief for hot flashes

WSS

Readout LOUD podcast: live from JPM 2024

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

HHS names first

Eli Lilly’s Mounjaro succeeds in second weight

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

hotspot

knowledge

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Supreme Court strikes down use of affirmative action

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Medicare proposal to cover medical devices draws a mixed reaction

How to fix the rural physician shortage in the U.S.

BioMarin wins approval for gene therapy to treat hemophilia A

The SUPPORT Act is critical to fighting the opioid crisis

23andMe had bad news about my health. I wish a person had delivered it

JPM 2024: Verve Therapeutics looks to mainstream genome editing

leisure time

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Millions may soon lose Medicaid when they don't have to

FDA approves first new drug developed for postpartum depression

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Patients, doctors are clashing about side effects of hormonal birth control

Idaho abortion case may prompt more restrictions in other states

focus

Wikipedia

leisure time

Wikipedia